Tags

Type your tag names separated by a space and hit enter

[Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer].
Ai Zheng. 2006 Jul; 25(7):818-22.AZ

Abstract

BACKGROUND & OBJECTIVE

YH-16, a new recombinant angiogenesis inhibitor, has demonstrated synergetic effects with chemotherapy in non-small-cell lung cancer treatment in stage II clinical trial. This study was to investigate the effect of YH-16 on liver metastases from colon cancer.

METHODS

Inhibitory concentration 50% (IC(50)) of YH-16 on vascular endothelial cells and colon cancer cell line CT26 was determined by MTT assay. Furthermore, the mouse mode of colon cancer liver metastases was established by inoculating CT26 cells into the subcapsule of spleen. 60 mice were randomly divided into four groups: control group (0 mg/kg), low-dose YH-16 group (0.40 mg/kg), medium-dose YH-16 group (0.75 mg/kg) and high-dose YH-16 group (1.5 mg/kg). The numbers of liver metastases were examined 2 weeks after drug injection. The expression of vascular endothelial growth factor (VEGF) was detected by immunohistochemical method in liver metastases, and tumor microvessel density (MVD) was measured by immunostaining using factor VIII monocolonal antibody.

RESULTS

Proliferation of CT26 and vascular endothelial cells was inhibited by YH-16, which the IC(50) was (2.16+/-0.28) microg/ml and (0.64+/-0.10) microg /ml, respectively. In vivo, the liver metastasis rates in control, low-dose, medium-dose and high-dose groups were 100%, 92.3%, 80% and 73.3%, respectively (P<0.05). However, YH-16 did not inhibit the growth of spleen tumors of which median volumes were 1.180 cm(3), 1.201 cm(3), 0.887 cm(3) and 0.781 cm(3), respectively (P>0.05). There was no difference of VEGF expression in liver metastases among the four groups. Moreover, MVD was 65.00+/-9.58, 58.15+/-8.81, 51.60+/-7.10 and 44.53+/-11.47 in the four groups. MVD in medium-dose and high-dose YH-16 groups was lower than that in control group and MVD was lower in high-dose group than that in medium-dose and low-dose groups (P<0.05).

CONCLUSION

Angiogenesis inhibitor YH-16 can inhibit liver metastases from colorectal cancer.

Authors+Show Affiliations

State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong Province, 510060, P. R. China. zhouzhiw@pub.guangzhou.gd.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

16831270

Citation

Zhou, Zhi-Wei, et al. "[Inhibitory Effect of Angiogenesis Inhibitor YH-16 On Liver Metastases From Colorectal Cancer]." Ai Zheng = Aizheng = Chinese Journal of Cancer, vol. 25, no. 7, 2006, pp. 818-22.
Zhou ZW, Wan DS, Wang GQ, et al. [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]. Ai Zheng. 2006;25(7):818-22.
Zhou, Z. W., Wan, D. S., Wang, G. Q., Ren, J. Q., Lu, Z. H., Lin, S. X., Tang, S. X., Ye, Y. L., & Chen, G. (2006). [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]. Ai Zheng = Aizheng = Chinese Journal of Cancer, 25(7), 818-22.
Zhou ZW, et al. [Inhibitory Effect of Angiogenesis Inhibitor YH-16 On Liver Metastases From Colorectal Cancer]. Ai Zheng. 2006;25(7):818-22. PubMed PMID: 16831270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]. AU - Zhou,Zhi-Wei, AU - Wan,De-Sen, AU - Wang,Guo-Qiang, AU - Ren,Jing-Qing, AU - Lu,Zhen-Hai, AU - Lin,Su-Xia, AU - Tang,Shao-Xian, AU - Ye,Yan-Li, AU - Chen,Gong, PY - 2006/7/13/pubmed PY - 2009/5/29/medline PY - 2006/7/13/entrez SP - 818 EP - 22 JF - Ai zheng = Aizheng = Chinese journal of cancer JO - Ai Zheng VL - 25 IS - 7 N2 - BACKGROUND & OBJECTIVE: YH-16, a new recombinant angiogenesis inhibitor, has demonstrated synergetic effects with chemotherapy in non-small-cell lung cancer treatment in stage II clinical trial. This study was to investigate the effect of YH-16 on liver metastases from colon cancer. METHODS: Inhibitory concentration 50% (IC(50)) of YH-16 on vascular endothelial cells and colon cancer cell line CT26 was determined by MTT assay. Furthermore, the mouse mode of colon cancer liver metastases was established by inoculating CT26 cells into the subcapsule of spleen. 60 mice were randomly divided into four groups: control group (0 mg/kg), low-dose YH-16 group (0.40 mg/kg), medium-dose YH-16 group (0.75 mg/kg) and high-dose YH-16 group (1.5 mg/kg). The numbers of liver metastases were examined 2 weeks after drug injection. The expression of vascular endothelial growth factor (VEGF) was detected by immunohistochemical method in liver metastases, and tumor microvessel density (MVD) was measured by immunostaining using factor VIII monocolonal antibody. RESULTS: Proliferation of CT26 and vascular endothelial cells was inhibited by YH-16, which the IC(50) was (2.16+/-0.28) microg/ml and (0.64+/-0.10) microg /ml, respectively. In vivo, the liver metastasis rates in control, low-dose, medium-dose and high-dose groups were 100%, 92.3%, 80% and 73.3%, respectively (P<0.05). However, YH-16 did not inhibit the growth of spleen tumors of which median volumes were 1.180 cm(3), 1.201 cm(3), 0.887 cm(3) and 0.781 cm(3), respectively (P>0.05). There was no difference of VEGF expression in liver metastases among the four groups. Moreover, MVD was 65.00+/-9.58, 58.15+/-8.81, 51.60+/-7.10 and 44.53+/-11.47 in the four groups. MVD in medium-dose and high-dose YH-16 groups was lower than that in control group and MVD was lower in high-dose group than that in medium-dose and low-dose groups (P<0.05). CONCLUSION: Angiogenesis inhibitor YH-16 can inhibit liver metastases from colorectal cancer. UR - https://www.unboundmedicine.com/medline/citation/16831270/[Inhibitory_effect_of_angiogenesis_inhibitor_YH_16_on_liver_metastases_from_colorectal_cancer]_ L2 - http://www.cancercommun.com/fulltextnew.asp?y=2006&amp;m=7&amp;ym=818 DB - PRIME DP - Unbound Medicine ER -